GlassScriptPhysician profile
Daniel G Chong
NPI 1942462601
$14,687.77
in general payments reported to CMS, 2019-2025
41 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $80.50 · 2021: $84.46 · 2022: $148 · 2023: $671 · 2024: $1,096 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.35 |
| Education | $137.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $6,571.96 | 2019 | |
| Janssen Biotech, INC. | $5,215.97 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $271.31 | 2019-2025 | Imfinzi, Enhertu |
| Amgen INC. | $243.91 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Gilead Sciences, INC. | $207.70 | 2019-2024 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $190.35 | 2023-2025 | |
| Daiichi Sankyo INC. | $173.67 | 2023-2025 | Injectafer, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $173.04 | 2021-2025 | Opdivo |
| Pfizer INC. | $161.19 | 2019-2025 | |
| Abbvie INC. | $114.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $111.59 | 2020-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Glaxosmithkline, LLC. | $104.36 | 2023-2025 | Jemperli, Zejula |
| Astellas Pharma US INC | $92.52 | 2020-2024 | Padcev, Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $85.49 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Rigel Pharmaceuticals, INC. | $79.76 | 2025 | Gavreto, Rezlidhia, Tavalisse |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $78.77 | 2019-2023 | Cabometyx |
| Genentech USA, INC. | $74.57 | 2023-2025 | Lunsumio, Polivy, Tecentriq |
| Ipsen Biopharmaceuticals, INC | $72.03 | 2023-2024 | Somatuline Depot, Onivyde, Tazverik |
| Celgene Corporation | $71.28 | 2024-2025 | Reblozyl |
| Incyte Corporation | $48.21 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Array Biopharma INC | $44.54 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Alexion Pharmaceuticals, INC. | $42.77 | 2023-2024 | Ultomiris |
| Coherus Oncology, INC. | $37.21 | 2023-2024 | |
| Iovance Biotherapeutics, INC. | $35.53 | 2025 | Amtagvi |
| Pharmacyclics LLC, An Abbvie Company | $34.56 | 2023 | Imbruvica, Epkinly |
| Myriad Genetic Laboratories, INC. | $33.54 | 2023 | Myrisk |
| Organon LLC | $32.80 | 2023-2024 | Ontruzant |
| Genmab U.S., INC. | $32.32 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $30.84 | 2022 | |
| Eisai INC. | $30.34 | 2019-2024 | |
| Beigene USA, INC. | $27.14 | 2022 | |
| Stemline Therapeutics INC. | $26.62 | 2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $23.44 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $22.46 | 2025 | |
| Mirati Therapeutics, INC. | $21.33 | 2023 | Krazati |
| Emd Serono, INC. | $18.97 | 2025 | |
| Medtronic, INC. | $18.75 | 2024 | Synchromedii |
| Adc Therapeutics America, INC. | $17.91 | 2024 | |
| Lilly USA, LLC | $14.38 | 2024 | Verzenio, Jaypirca, Retevmo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.